ANTIBODY MICROARRAY FOR DETECTION OF TUMOR MARKERS

用于检测肿瘤标志物的抗体微阵列

• 批准号: 6485026
• 负责人: MICHAEL S WILSON
• 金额: $ 10万
• 依托单位: EIC LABORATORIES, INC.
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-04-15 至 2003-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6485026
• 关键词: antibody; biomarker; carcinoembryonal antigen; electrochemistry; enzyme linked immunosorbent assay; immunologic assay /test; immunologic substance development /preparation; iridium; microarray technology; microelectrodes; neoplasm /cancer diagnosis; neoplasm /cancer immunology; nucleic acid quantitation /detection; prostate specific antigen; tumor antigens

DESCRIPTION (provided by applicant): The development of stable antibody microarrays for the simultaneous detection and quantification of multiple tumor markers in blood, urine and tissue is proposed. The arrays will increase the diagnostic value of tumor markers in cancer diagnosis, assessment of treatment, and basic research in molecular profiling, by allowing the simultaneous measurement of multiple groups of markers associated with the same types of cancer. The key innovation is the use of an electrochemically grown matrix (iridium oxide) to immobilize antibodies and maintain their activity, and its application with well-established microelectrode array fabrication methods to produce stable protein microarrays. All the components can be readily miniaturized to circuit board level with very modest power requirements. The design of the arrays is such that they can perform electrochemical simultaneous multianalyte immunoassays (SMAI) from single, small volume samples. In Phase I we will demonstrate the simultaneous detection and quantification of two tumor markers, prostate-specific antigen (PSA) and carcinoembryonic antigen (CEA) using SMAI in order to provide proof-of-concept validation of our antibody microarray system. PROPOSED COMMERCIAL APPLICATION: Antibody arrays will be used to detect and quantify multiple tumor markets from body fluids or extracts of cancer tissues and cultured cells. Potential uses of cancer markers include screening in the general population, clinical staging of cancer, estimating tumor volume, monitoring response to therapy, detecting the recurrence of cancer and basic research in the molecular profiling of cancer.

描述（申请人提供）：稳定抗体的开发 用于同时检测和定量多种肿瘤的微阵列 提出了血液、尿液和组织中的标记物。阵列将增加 肿瘤标志物在癌症诊断、治疗评估中的诊断价值 和分子谱分析的基础研究，通过允许同时进行 测量与相同类型相关的多组标记物 癌症。关键的创新是使用电化学生长的基质 （氧化铱）固定抗体并保持其活性，及其 应用成熟的微电极阵列制造方法 产生稳定的蛋白质微阵列。所有组件都可以轻松地 小型化至电路板级，功率要求非常适中。这 阵列的设计使得它们可以同时进行电化学 对单个小体积样品进行多分析物免疫分析 (SMAI)。第一阶段 我们将展示两种肿瘤的同时检测和定量 标志物，前列腺特异性抗原（PSA）和癌胚抗原（CEA） 使用 SMAI 为我们的抗体提供概念验证 微阵列系统。 拟议的商业应用： 抗体阵列将用于从体液或体液中检测和量化多个肿瘤市场 癌组织和培养细胞的提取物。 癌症标记物的潜在用途包括 一般人群筛查、癌症临床分期、估计肿瘤体积、 监测治疗反应、检测癌症复发和基础研究 癌症的分子谱分析。